Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) Director Riad Hussein El-Dada sold 175,000 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $0.23, for a total transaction of $40,250.00. Following the transaction, the director directly owned 175,000 shares in the company, valued at $40,250. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Greenland Mines Ltd. Common Stock Stock Performance
NASDAQ GRML traded up $0.04 during trading on Friday, reaching $0.25. The company’s stock had a trading volume of 3,924,253 shares, compared to its average volume of 3,484,479. The business’s fifty day moving average price is $0.39 and its 200-day moving average price is $0.39. Greenland Mines Ltd. Common Stock has a twelve month low of $0.21 and a twelve month high of $1.65. The firm has a market cap of $34.53 million, a price-to-earnings ratio of -0.78 and a beta of 6.94.
Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) last announced its earnings results on Wednesday, May 20th. The company reported ($0.15) earnings per share for the quarter.
Institutional Trading of Greenland Mines Ltd. Common Stock
Analyst Ratings Changes
Several brokerages have weighed in on GRML. Weiss Ratings upgraded Greenland Mines Ltd. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 9th. Wall Street Zen upgraded Greenland Mines Ltd. Common Stock to a “sell” rating in a research note on Saturday, May 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Greenland Mines Ltd. Common Stock has a consensus rating of “Sell”.
Read Our Latest Research Report on GRML
About Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Further Reading
- Five stocks we like better than Greenland Mines Ltd. Common Stock
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Greenland Mines Ltd. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenland Mines Ltd. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
